Newsgroup: it.economia.borsa.estero
Titolo: NEWS----BICO-----NEWS Positivissima !!!

BICO, Inc.'s Subsidiary, Diasensor.com, Expands Alliance with
MicroIslet, Inc. After Significant Milestone is Achieved
PITTSBURGH, Aug. 22 /PRNewswire/ -- BICO, Inc. (OTC Bulletin Board:
BICO - news) subsidiary Diasensor.com, Inc., announced today that
following a significant milestone achievement, the Company expanded
its alliance with San Diego, CA-based MicroIslet, Inc. with the
acquisition of an additional ten percent of the company, increasing
Diasensor.com's holdings to twenty percent.
The significant milestone achieved is the state of normal glycemia as
evidenced by blood glucose measurements, HbA1c results, and glucose
tolerance testing of one previously insulin dependent non-human
primate. The transplant recipient had severe diabetes with blood
glucose readings in excess of 600mg/dl prior to the procedure, which
has now restored proper glucose control for a period well into the
fourth month, giving the primate consistent blood glucose readings
between 80 mg/dl and 110 mg/dl. Of particular interest to the diabetes
community is the fact that the MicroIslet approach does not have the
limitations related to supply of islets from human donors or the need
for immuno-supression regimens, according to John F. Steel, CEO of
MicroIslet, Inc.
This milestone was met in the course of a MicroIslet-sponsored
research project conducted in the laboratory of Dr. Emmanuel Opara,
Ph.D./ Director of Islet Transplant Research at Duke University
Medical Center. Full results will be published when the project is
complete. MicroIslet has licensed several technologies from Duke
University related to Islet Cell Transplantation for insulin dependent
diabetes. The technology developed by Dr. Opara represents a unique
method for isolation, culture, storage, and immunoprotection of
transplanted Islet cells.
More than 16 million people in the U.S. are currently living with
diabetes, and approximately 4 million of these people require daily
insulin therapy to help them manage their disease. This population
would benefit the greatest from transplanted islets to restore
normally functioning, insulin-producing cells instead of treating
symptoms of the disease. Estimates indicate that in excess of 100
billion dollars is spent annually in the U.S. on direct and indirect
costs associated with diabetes.
Fred E. Cooper, CEO of BICO, Inc., stated, ``BICO and Diasensor.com
are elated with the progress realized by MicroIslet in this research
project. This expanded alliance and investment in MicroIslet
demonstrates the ongoing commitment of Diasensor.com and BICO, its
parent, to work toward a cure for diabetes and improved quality of
life for those who suffer from the disease.''
BICO, Inc. (formerly known as Biocontrol Technology, Inc.) has its
corporate offices in Pittsburgh, PA and is involved in the development
and manufacture of biomedical devices and environmental products.
Subsidiary Diasensor.com owns the patents, technology, marketing, and
distribution rights to the Diasensor 2000 noninvasive glucose monitor,
which was developed by BICO and is currently in the FDA approval
process. BICO owns 52% of Diasensor.com, which is also located in
Pittsburgh, PA. 

 wrote in message
EnKiOb3li2PppC...@4ax.com...


 wrote in message
ezzo5.117679$dF5.1...@news.infostrada.it...
